Alembic Pharmaceuticals Limited

rs,

Date: 15th May, 2026 To, The Manager, Department of Corporate Services, BSE Limited P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 Scrip Code: 533573 To, The Manager, Listing Department,

INR 18.48

tance. Alembic Pharmaceuticals Ltd. Investor Presentation Q4 FY26 2 Quarterly Snapshot Revenue INR 18.48 Bn +4% YoY Revenue Profitability Key Highlights EBIDTA before R&D INR 4.55 Bn EBIDTA Margin ~25

4%

Pharmaceuticals Ltd. Investor Presentation Q4 FY26 2 Quarterly Snapshot Revenue INR 18.48 Bn +4% YoY Revenue Profitability Key Highlights EBIDTA before R&D INR 4.55 Bn EBIDTA Margin ~25% +8%

INR 4.55

Snapshot Revenue INR 18.48 Bn +4% YoY Revenue Profitability Key Highlights EBIDTA before R&D INR 4.55 Bn EBIDTA Margin ~25% +8% YoY R&D 11% of revenue +39% YoY India Branded Business Achieved a 4% Y

25%

8 Bn +4% YoY Revenue Profitability Key Highlights EBIDTA before R&D INR 4.55 Bn EBIDTA Margin ~25% +8% YoY R&D 11% of revenue +39% YoY India Branded Business Achieved a 4% YoY growth with quarte

8%

+4% YoY Revenue Profitability Key Highlights EBIDTA before R&D INR 4.55 Bn EBIDTA Margin ~25% +8% YoY R&D 11% of revenue +39% YoY India Branded Business Achieved a 4% YoY growth with quarterly r

11%

enue Profitability Key Highlights EBIDTA before R&D INR 4.55 Bn EBIDTA Margin ~25% +8% YoY R&D 11% of revenue +39% YoY India Branded Business Achieved a 4% YoY growth with quarterly revenues of I

39%

ty Key Highlights EBIDTA before R&D INR 4.55 Bn EBIDTA Margin ~25% +8% YoY R&D 11% of revenue +39% YoY India Branded Business Achieved a 4% YoY growth with quarterly revenues of INR 5.68 billion.

INR 5.68 billion

% of revenue +39% YoY India Branded Business Achieved a 4% YoY growth with quarterly revenues of INR 5.68 billion. Pre R&D EBITDA Pre R&D EBITDA margin increased from 24% to 25%; 8% year-over-year growth. US Fo

24%

with quarterly revenues of INR 5.68 billion. Pre R&D EBITDA Pre R&D EBITDA margin increased from 24% to 25%; 8% year-over-year growth. US Formulation The business recorded a 11% year-over-year incr

2%

igher filings compared to the previous year. Ex-US Formulation The quarter recorded De-Growth of -2% year-over- year, while continued focus remains on expanding offerings and strengthening market rea

INR 2.03

while continued focus remains on expanding offerings and strengthening market reach. Reported PAT INR 2.03 Bn Net Profit Margin 11% +29% YoY API The business reported consistent growth of 2% in Q4. Alem